Sector News

Stada CEO Retzlaff resigns from office

August 16, 2016
Life sciences

Today STADA Arzneimittel AG and its long-serving chairman of the management board Hartmut Retzlaff agreed on terminating their service relationship due to personal circumstances.

Hartmut Retzlaff has resigned from his office as member of the management board, which he had laid down since June 5, 2016, with effect as of August 15, 2016. Hartmut Retzlaff will be released from his duty to perform services under his board member service agreement until the agreed termination of the service agreement on December 31, 2016.

In accordance with Number 4.2.3 Deutscher Corporate Governance Kodex, the German corporate governance code, the payments agreed between STADA and Hartmut Retzlaff on the premature termination of his contract, comprising of a severance payment and the continued payment of his salary until the end of contract on 31 December 2016, do not exceed the severance pay cap of two years‘ compensation.

Source: Stada

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.